So what do you think the value of Remestemcel post approval would be? I provide just one exsample. What do you think MSB would do with US $ 4 billion cash on hand?
Takeda? Spent 4 billion and they have this to add.
Takeda expects that the financial impact on its consolidated operating results for the fiscal year ending March 31, 2023 (FY2022), as a result of the completion of the transaction, is immaterial. There is no change in Takeda’s FY2022 consolidated forecasts for operating results or the management guidance.
Ann: FDA Schedules GvHD Pre-License Manufacturing Inspection, page-182
-
- There are more pages in this discussion • 94 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
96.0¢ |
Change
-0.010(1.03%) |
Mkt cap ! $1.096B | |||
| Open | High | Low | Value | Volume |
| 98.0¢ | 98.5¢ | 95.0¢ | $2.617M | 2.715M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 107932 | 95.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 96.0¢ | 34142 | 1 |
View Market Depth
| Last trade - 16.10pm 13/08/2024 (20 minute delay) ? |
| MSB (ASX) Chart |